BenchSci raises $70M Series D for drug discovery software; Zentalis touts PhIb ovarian cancer data

Canada’s BenchSci has raised $70 million in a Series D round designed to scale its AI drug discovery platform for scientists working in preclinical research.

The company boasts thousands of clients for its software, including 16 of the top 20 pharmaceutical companies. On the platform, researchers can get a digest...

Click to view original post